Drug
MR 130a 01 Contraceptive Transdermal
MR 130a 01 Contraceptive Transdermal: highest development phase Phase 2, developed by Viatris. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Viatris
Trials
| Drug | Phase | Indication |
|---|---|---|
| MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) NCT07365904 | Phase 2 | Contraception |
Latest
No recent events.
Follow MR 130a 01 Contraceptive Transdermal on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.